Article
Rational combination therapy with PARP and MEK inhibitors capitalizes on therapeutic liabilities in RAS mutant cancers.
Science translational medicine - 31 May 2017
Sun Chaoyang, Fang Yong, Yin Jun, Chen Jian, Ju Zhenlin, Zhang Dong, Chen Xiaohua, Vellano Christopher P, Jeong Kang Jin, Ng Patrick Kwok-Shing, Eterovic Agda Karina B, Bhola Neil H, Lu Yiling, Westin Shannon N, Grandis Jennifer R, Lin Shiaw-Yih, Scott Kenneth L, Peng Guang, Brugge Joan, Mills Gordon B
Abstract excerpt
Mutant RAS has remained recalcitrant to targeted therapy efforts. We demonstrate that combined treatment with poly(adenosine diphosphate-ribose) polymerase (PARP) inhibitors and mitogen-activated protein kinase (MAPK) kinase (MEK) inhibitors evokes unanticipated, synergistic cytotoxic effects in vitro and in vivo in multiple RAS mutant tumor models across tumor lineages where RAS mutations are prevalent. The...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.